15 Multiple Myeloma Clinical Trials in Cincinnati, OH (2026)

Q: How do I join a clinical trial in Cincinnati?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Cincinnati research site will contact you.

Recruiting Multiple Myeloma Studies in Cincinnati

NCT00267501Recruiting

Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders

The purpose of this study is to elucidate the mechanisms underlying eosinophil growth, survival, migration, and function and to investigate and further characterize the pathophysiology of, clinical ma...

Cincinnati, OH5,000 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT05750498Recruiting

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD). This study will...

Cincinnati, OH800 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT06892522Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, in...

Cincinnati, OHPHASE1602 participantsAbbVie

View Study Details

NCT07555938Recruiting

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple my...

Cincinnati, OHPHASE3380 participantsHoffmann-La Roche

View Study Details

NCT06750731Recruiting

Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

The goal of this observational study is to assess the feasibility and effectiveness of a remote monitoring digital health system on adherence, clinical outcomes, and healthcare utilization in patients...

Cincinnati, OH200 participantsMercy Medical Center

View Study Details

NCT03178630Recruiting

MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease

Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents. This is...

Cincinnati, OH150 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT03175471Recruiting

MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all...

Cincinnati, OH115 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT05972135Recruiting

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients...

Cincinnati, OHPHASE2100 participantsSCRI Development Innovations, LLC

View Study Details

NCT06974786Recruiting

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary ob...

Cincinnati, OHPHASE2100 participantsSCRI Development Innovations, LLC

View Study Details

NCT07195123Recruiting

Evaluation of the SMART IBD App in Pediatric IBD

The objective of this trial is to test whether a smartphone app, SMART-IBD, is effective in improving medication adherence and self-management skills in adolescents with IBD. The investigators will co...

Cincinnati, OHNA70 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT05722418Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to deter...

Cincinnati, OHPHASE150 participantsCaribou Biosciences, Inc.

View Study Details

NCT06533098Recruiting

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT)....

Cincinnati, OHPHASE350 participantsJanssen Research & Development, LLC

View Study Details

NCT04925375Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promis...

Cincinnati, OHPHASE238 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT07368972Recruiting

Study of DISC-0974-201 in Participants With IBD and Anemia

This is a Phase 2, multicenter, randomized, double-blind placebo-controlled study of DISC-0974 to evaluate safety, tolerability, and efficacy in participants with IBD and anemia of inflammation....

Cincinnati, OHPHASE221 participantsDisc Medicine, Inc

View Study Details

NCT05642455Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

Cincinnati, OHPHASE120 participantsAdaptimmune

View Study Details

About Multiple Myeloma Clinical Trials in Cincinnati

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 15 multiple myeloma clinical trials recruiting participants in Cincinnati, OH. These studies are seeking a combined 7,696 participants. Research is being sponsored by Children's Hospital Medical Center, Cincinnati, AbbVie, Hoffmann-La Roche and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Cincinnati — FAQ

Are there multiple myeloma clinical trials in Cincinnati?

Yes, there are 15 multiple myeloma clinical trials currently recruiting in Cincinnati, OH. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Cincinnati?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Cincinnati research site will contact you about next steps.

Are clinical trials in Cincinnati free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Cincinnati studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 15 active trials in Cincinnati are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated September 3, 2026 from ClinicalTrials.gov